(Q46856135)

25 December 2017

title

Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors (English)

1 reference

25 December 2017

author

Gauri J Sabnis

series ordinal

2

1 reference

25 December 2017

author name string

Luciana F Macedo

series ordinal

1

1 reference

25 December 2017

Angela Brodie

series ordinal

3

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

25 December 2017

published in

Cancer

1 reference

25 December 2017

volume

112

1 reference

25 December 2017

issue

3 Suppl

1 reference

25 December 2017

page(s)

679-688

1 reference

25 December 2017

The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

The role of mitogen-activated protein (MAP) kinase in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23191

7 January 2021

Identifiers

DOI

10.1002/CNCR.23191

1 reference

25 December 2017

PubMed ID

18072255

1 reference

25 December 2017